Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Xbrane Biopharma AB ( (SE:XBRANE) ).
Xbrane Biopharma has addressed numerous stakeholder questions following a delay in FDA approval for its product Lucamzi, known as Ximluci in the U.S., and its Q3 report. The company has provided detailed responses to these inquiries, highlighting its commitment to transparency and stakeholder engagement amid regulatory challenges.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK11.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology, which offers significantly lower production costs compared to competitors. The company has a portfolio of biosimilar candidates targeting an estimated EUR 23 billion in annual peak sales of the respective reference products. Xbrane’s lead candidate, Ximluci, has received market authorization in Europe and was launched in 2023. The company is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 162,579
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK230.8M
For detailed information about XBRANE stock, go to TipRanks’ Stock Analysis page.